ALLO News and Press, Allogene Therapeutics Inc. From 10/13/21

Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...

Adding to post-market losses on Tuesday, CRISPR Therapeutics (NASDAQ:CRSP) has slipped another ~8.2% in early hours after the company’s gene-edited allogeneic CAR-T cell therapy CTX110 failed to excite investors with data from an early-stage trial in CD19+ B-cell maligna...

The situation around the clinical hold is unclear and will take at least a few months to resolve. The risk-reward opportunity is very high. I am taking a risk and buying. For further details see: Allogene Therapeutics: I Am Buying On The Clinical Hold Dip

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks and U.S. Treasurys fell Friday after a weak jobs report added to speculation about the Federal Reserve's plan to taper its bond-buying...

While stocks finished fractionally lower on Friday after a disappointing payroll report, oil prices continued their steady climb, driving to a multi-year high. This powered stocks in the sector, with APA Corp. (NASDAQ:APA), Pioneer Natural Resources (NYSE:PXD), Hess Corp. (NYSE:HES) and EOG R...

Shares of Allogene Therapeutics Inc ( NASDAQ: ALLO ) tanked 45% to $13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial. The sharp decline wiped millions off Allogene’s market cap, leaving the California-based firm with a valuation of $1.90 billion. ...

The stock market posted mixed results on Friday morning, as investors continued to wrestle with countervailing factors in making their investment decisions. As of 11:45 a.m. EDT, the Nasdaq Composite (NASDAQINDEX: ^IXIC) was trailing other major benchmarks, falling about a quarter p...

Shares of the off-the-shelf cell therapy company Allogene Therapeutics (NASDAQ: ALLO) are ending the week on a sour note. The biotech's stock is down by a jaw-dropping 44% as of 11:36 a.m. EDT Friday morning. Allogene's shares are plunging today after the U.S. Food and Drug Admi...

Gainers: ChemoCentryx (NASDAQ:CCXI) +70%. Renren (NYSE:RENN) +48%. DatChat (NASDAQ:DATS) +32%. ReShape Lifesciences (NASDAQ:RSLS) +29%. Huadi International (NASDAQ:HUDI) +24%. Voyager (NASDAQ:VYGR) +22%. NextPlay Technologies (NASDAQ:NXTP) +21%. Tian Ruixiang (NASDAQ:TIRX) +20%. Lilium (NASDA...

Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,&#x...